Recombinant α-2 Interferon with or Without Hepatic Artery Embolization in the Treatment of Midgut Carcinoid Tumours a Preliminary Report

Reference

• Biörck G, Axén O, Thorson Å. Unusual cyanosis in a boy with congenital pulmonary stenosis and tricuspid insufficiency. Fatal outcome after angiocardiography. Am Heart J 1952; 44: 143–8
   PubMed Web of Science ®Google Scholar
• Davis Z, Moertel C G, McIlrath DC. The malignant carcinoid syndrome. Surg Gynecol Obstet 1973; 137: 637–44
   PubMedGoogle Scholar
• Berge T, Linell F. Carcinoid tumors. Acta Pathol Microbiol Scand 1976; 84: 322–30
   Google Scholar
• Davies AJ. Carcinoid tumors (argentaffinomata). Ann Royal Coll Surg Engl 1959; 25: 277–97
   PubMedGoogle Scholar
• Moertel CG. Treatment of the carcinoid tumor and the malignant carcinoid syndrome. J Clin Oncol 1983; 1: 727–40
   PubMed Web of Science ®Google Scholar
• Kvols LK. Metastatic carcinoid tumors and the carcinoid syndrome. A selective review of chemotherapy and hormonal therapy. Am J Med 1986; 81: 49–55, Suppl 6B
   PubMed Web of Science ®Google Scholar
• Bengmark S, Nobin A, Leppsson B, Tranberg S. Transient repeated dearterialization combined with intraarterial infusion of oncolytic drugs in the treatment of liver tumors. Recent results. Cancer Res 1983; 86: 68–74
   Google Scholar
• Maton P N, Camilleri M, Griffin G, et al. The role of hepatic embolization in the carcinoid syndrome. Br Med J 1983; 287: 932–5
   PubMed Web of Science ®Google Scholar
• Mårtensson H, Nobin A, Bengmark S, Lunderquist A, Owman T, Sandén G. Embolization of the liver in the management of metastatic carcinoid tumors. J Surg Oncol 1984; 27: 152–8
   PubMed Web of Science ®Google Scholar
• Mitty H A, Warner R RP, Newman L H, Train J S, Pames IH. Control of carcinoid syndrome with hepatic artery embolization. Radiology 1985; 155: 623–6
   PubMed Web of Science ®Google Scholar
• Stockmann F, Creutzfeldt W. Approach to hepatic involvement by endocrine tumors of the gastrointestinal tract. Semin Liver Dis 1988; 8: 254–62
   PubMed Web of Science ®Google Scholar
• Isaacs A, Lindemann J. Virus interference: I. The interferon. Proc R Soc (B) 1957; 147: 258–67
   PubMed Web of Science ®Google Scholar
• Hersey P. The evolving role of alpha interferon in the treatment of malignancies. Aust NZ J Med 1986; 16: 425–37
   PubMedGoogle Scholar
• Cantell K, Hirvonen S. Large scale production of human leukocyte interferon containing 10 units/ml. J Gen Virol 1978; 39: 541–3
   PubMed Web of Science ®Google Scholar
• Nagat S, Taira H, Hall A, et al. Synthesis in E. coli of a polypeptide with human leukocyte interferon activity. Nature 1980; 284: 316–20
   PubMedGoogle Scholar
• öberg K, Funa K, Alm G. Effects of leucocyte interferon on clinical symptoms and hormone levels in patients with midgut carcinoid tumors and carcinoid syndrome. N Engl J Med 1983; 309: 129–33
   PubMed Web of Science ®Google Scholar
• Hanssen L E, Schrumpf E, Kolbenstvedt A N, Tausjö J, Dolva L. Recombinant human interferon alpha-2b in the treatment of malignant metastatic carcinoid tumors. J Interferon Res 1987; 7: 735
   Google Scholar
• Froelich J C, Bloomgarten Z T, Oates J A, McGuigan J E, Rabinowitz D. The carcinoid flush. Provocation by pentagastrin and inhibition by somatostatin. N Engl J Med 1978; 299: 1055–7
   PubMed Web of Science ®Google Scholar
• Kvols L K, Martin J K, Marsh H M, Moertel CG. Rapid reversal of carcinoid crises with a somatostatin analogue. N Engl J Med 1985; 313: 1229–30
   PubMed Web of Science ®Google Scholar
• Kvols L K, Moertel C G, O'Connell M J, Schutt A J, Rubin J, Hahn RG. Treatment of the malignant carcinoid syndrome: evaluation of a long acting somatostatin analogue. N Engl J Med 1986; 315: 663–6
   PubMed Web of Science ®Google Scholar
• Feldman JM. Urinary serotonin in the diagnosis of carcinoid tumors. Clin Chem 1986; 32: 840–4
   PubMed Web of Science ®Google Scholar
• Spiegel RJ. Intron A (Interferon alfa-2b): clinical overview and future directions. Cln Oncol 1986; 13: 89–101, Suppl 2
   Google Scholar
• Gutterman J U, Fine S, Quesada J, et al. Recombinant leukocyte A interferon: pharmacokinetics, single-dose tolerance, and biologic effects in cancer patients. Ann Intern Med 1982; 96: 549–56
   PubMed Web of Science ®Google Scholar
• Moertel C G, Sauer W G, Dockerty M B, Baggenstoss AH. Life history of the carcinoid tumor of the small intestine. Cancer 1961; 14: 901–12
   PubMed Web of Science ®Google Scholar
• Goodwin JD. Carcinoid tumors. An analysis of 2837 cases. Cancer 1975; 36: 560–9
   PubMed Web of Science ®Google Scholar
• Zeitels J, Naunheim K, Kaplan E L, Straus F II. Carcinoid tumors—a 37 years experience. Arch Surg 1982; 117: 732–7
   PubMedGoogle Scholar
• Norheim I, öberg K, Theodorsson-Norheim E, et al. Malignant carcinoid tumors: an analysis of 103 patients with regard to tumor localisation, hormone production and survival. Ann Surgery 1987; 206: 115–25
   PubMed Web of Science ®Google Scholar
• Theodorsson-Norheim E, Norheim I, öberg K, Brodin E, Lundberg J M, Tatemoto K. Neuropeptide K: a major tachykinin in plasma and tumor tissue from carcinoid patients. Biochem Biophys Res Comm 1985; 131: 77–83
   PubMed Web of Science ®Google Scholar
• Norheim I, Theodorsson-Norheim E, Brodin E, öberg K. Tachykinins in carcinoid tumors. Their use as a tumor marker and possible role for the carcinoid flush. J Clin Endocrinol Met 1986; 63: 605–12
   PubMed Web of Science ®Google Scholar
• Jaffe BM. Prostaglandins and serotonin: nonpeptide diarrheogenic hormones. World J Surg 1979; 3: 565–78
   PubMedGoogle Scholar
• Roberts W C, Sjoerdsma A. The cardiac disease associated with the carcinoid syndrome (carcinoid heart disease). Am J Med 1964; 36: 5–34
   PubMed Web of Science ®Google Scholar
• Andersson T, Eriksson B, Hemmingsson A, Lindgren P G, öberg K. Angiography, computed tomography, magnetic resonance imaging and ultrasonography in detection of liver metastases from endocrine gastrointestinal tumours. Acta Radiol 1987; 28: 535–9
   PubMed Web of Science ®Google Scholar
• Herberman RB. Cancer therapy by biological response modifiers. Drug Res 1987; 37: 246–50
   Web of Science ®Google Scholar
• Spiegel RJ. The alpha interferons: clinical overview. Semin Oncol 1987; 14: 1–12, Suppl 2
   PubMed Web of Science ®Google Scholar
• Quesada J R, Talpaz M, Rios A, Kurzrock R, Gutterman JU. Clinical toxicity of interferons in cancer patients: a review. J Clin Oncol 1986; 4: 234–43
   PubMed Web of Science ®Google Scholar
• Torristi J, Berg C, Bonnem E, Dritschilo A. The combined use of interferon and radiotherapy in cancer management. Semin Oncol 1986; 13: 78–83, Suppl 2
   PubMed Web of Science ®Google Scholar
• Keane T J, Rider W D, Harwood A R, et al. Whole abdominal radiation in the management of metastatic gastrointestinal carcinoid tumor. Int J Radiat Oncol Biol Phys 1981; 7: 1519–21
   PubMed Web of Science ®Google Scholar
• Samlowski W E, Eyre H J, Sanse WT. Evaluation of the response of unresectable carcinoid tumors to radiotherapy. Int J Radiat Oncol Biol Phys 1986; 12: 301–5
   PubMed Web of Science ®Google Scholar